Meng ZW, Chang B, Sang LX. Use of curcumin and its nanopreparations in the treatment of inflammatory bowel disease. World J Gastroenterol 2024; 30(3): 280-282 [PMID: 38314128 DOI: 10.3748/wjg.v30.i3.280]
Corresponding Author of This Article
Li-Xuan Sang, MD, PhD, Professor, Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 39 Gliding Road, Tiexi District, Shenyang 110022, Liaoning Province, China. sanglixuan2008@163.com
Research Domain of This Article
Medicine, Research & Experimental
Article-Type of This Article
Letter to the Editor
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Jan 21, 2024; 30(3): 280-282 Published online Jan 21, 2024. doi: 10.3748/wjg.v30.i3.280
Use of curcumin and its nanopreparations in the treatment of inflammatory bowel disease
Zi-Wen Meng, Bing Chang, Li-Xuan Sang
Zi-Wen Meng, Li-Xuan Sang, Department of Gastroenterology, Shengjing Hospital of China Medical University, Shenyang 110022, Liaoning Province, China
Bing Chang, Department of Gastroenterology, the First Affiliated Hospital of China Medical University, Shenyang 110001, Liaoning Province, China
Author contributions: Meng ZW wrote the letter; Chang B and Sang LX supervised the manuscript draft; all authors contributed important intellectual content during drafting and revising of the manuscript.
Conflict-of-interest statement: There are no conflicts of interest to report.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Li-Xuan Sang, MD, PhD, Professor, Department of Gastroenterology, Shengjing Hospital of China Medical University, No. 39 Gliding Road, Tiexi District, Shenyang 110022, Liaoning Province, China. sanglixuan2008@163.com
Received: October 6, 2023 Peer-review started: October 6, 2023 First decision: December 6, 2023 Revised: December 12, 2023 Accepted: January 4, 2024 Article in press: January 4, 2024 Published online: January 21, 2024
Abstract
Inflammatory bowel disease (IBD) is a nonspecific inflammatory disease of the intestine that includes Crohn’s disease and ulcerative colitis. Because IBD is difficult to heal and easily relapses, it could worsen patient quality of life and increase economic burdens. Curcumin (CUR) is a bioactive component derived from the rhizome of turmeric (Curcuma longa). Many basic and clinical studies have shown that CUR can efficiently treat IBD by decreasing the activity of proinflammatory cytokines by communicating with transcription factors and signaling molecules. However, due to the limitations of being almost insoluble in aqueous solutions and having low oral bioavailability, it is important to select appropriate pharmaceutical preparations.
Core Tip: Curcumin (CUR) can efficiently decrease the activity of proinflammatory cytokines by communicating with transcription factors and signaling molecules. It is a new area of research that may be promising in the future to treat patients with inflammatory bowel disease, especially in patients with ulcerative colitis. How to improve the bioavailability of CUR in vivo was also discussed.
